Ultimovacs ASA (7UM.F)

Compare

0.1742

-0.0036

(-2.02%)

At close: January 31 at 3:29:01 PM GMT+1

Ultimovacs ASA (FRA:7UM) Q4 2024 Earnings Call Highlights: Strategic Merger and Financial Challenges

Despite significant financial losses and workforce reductions, Ultimovacs ASA's merger with Zelluna Immunotherapy aims to revolutionize cancer treatment with innovative TCRNK technology.

GuruFocus.com 11 hours ago

7UM.F
-2.02%
Ultimovacs ASA Reports Fourth Quarter 2024 Financial Results and Provides General Business Update

Oslo, January 31, 2025: Ultimovacs ASA ("Ultimovacs") (OSE ULTI), a clinical-stage biotechnology company developing novel immunotherapies against cancer, announces its fourth quarter 2024 results today. Conference call and webcast scheduled for January 31, 2025, at 09:00 (CET). Link to webcast here. Fourth Quarter 2024 Business Update Highlights On December 17, 2024, Ultimovacs announced an agreement to combine its business with Zelluna Immunotherapy AS and the intention to launch a fully commit

GlobeNewswire yesterday

ULTI.OL

ULTIO.OL
Ultimovacs ASA: Invitation to fourth quarter 2024 results webcast presentation

Oslo, January 27, 2025: Ultimovacs ASA (“Ultimovacs”) (OSE ULTI), a clinical-stage biotechnology company developing novel immunotherapies against cancer, invites to a webcast presentation of its fourth quarter 2024 results, on Friday, January 31, 2025. The presentation can be followed as a live webcast accessed through a link on www.ultimovacs.com at 09:00 CET on Friday, January 31, 2025. The webcast presentation will be available on the Ultimovacs website, and it will be possible to post questi

GlobeNewswire 5 days ago

ULTI.OL

ULTIO.OL
Ultimovacs ASA: Notification of major holdings

Oslo, 9 January 2025: Reference is made to the stock exchange notices published by Ultimovacs ASA (the "Company") on (i) 17 December 2024 regarding the contemplated business combination between the Company and Zelluna Immunotherapy AS (the "Business Combination") and the fully committed private placement with gross proceeds of approx. NOK 51.7 million (the "Private Placement") and (ii) today on 9 January 2025 regarding the approval by an extraordinary general meeting of the Company (the "EGM") o

GlobeNewswire 23 days ago

ULTI.OL

ULTIO.OL
Ultimovacs ASA: Notice of extraordinary general meeting on 9 January 2024 - CORRECTION

Oslo, 19 December 2024: Reference is made to the stock exchange notice published by Ultimovacs ASA (the "Company") on 17 December 2024 regarding the contemplated business combination between the Company and Zelluna Immunotherapy AS and the fully committed private placement and the stock exchange notice published at 07:00 CET today. In today's notice, one attachment was missing. All documents are included in this announcement, The Company's board of directors (the "Board") hereby calls for an ext

GlobeNewswire last month

ULTI.OL

ULTIO.OL
Ultimovacs ASA: Notice of extraordinary general meeting on 9 January 2024

Oslo, 19 December 2024: Reference is made to the stock exchange notice published by Ultimovacs ASA (the "Company") on 17 December 2024 regarding the contemplated business combination between the Company and Zelluna Immunotherapy AS and the fully committed private placement. The Company's board of directors (the "Board") hereby calls for an extraordinary general meeting on 9 January 2025 at 09:00 CET (the "EGM") to resolve upon the matters proposed by the Board in the attached EGM notice. The EGM

GlobeNewswire last month

ULTI.OL

ULTIO.OL
Key information relating to the potential subsequent repair offering to be carried out by Ultimovacs ASA

Reference is made to the stock exchange announcement by Ultimovacs ASA ("Ultimovacs" or the "Company") on 17 December 2024 regarding the agreement to combine its business with Zelluna Immunotherapy AS ("Zelluna"), the fully committed private placement (the "Private Placement"), and the intention to carry out a subsequent repair offering (the "Subsequent Offering") of up to 3,846,153 new shares at a subscription price per new share of NOK 2.60, directed towards shareholders of Ultimovacs or Zellu

GlobeNewswire last month

ULTI.OL

ULTIO.OL
Ultimovacs ASA – Mandatory notification of trade

Reference is made to the stock exchange announcement by Ultimovacs ASA (the "Company") on 17 December 2024 regarding the agreement to combine its business with Zelluna Immunotherapy AS (the "Business Combination") and the fully committed private placement (the "Private Placement" and together with the Business Combination, the "Transactions"). Please see the attached forms for information on the conditional allocation of shares in the Company to closely related parties of primary insiders in con

GlobeNewswire last month

ULTI.OL

ULTIO.OL
ULTIMOVACS ANNOUNCES AGREEMENT TO COMBINE ITS BUSINESS WITH ZELLUNA IMMUNOTHERAPY AND INTENTION TO LAUNCH FULLY COMMITTED PRIVATE PLACEMENT

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA OR JAPAN OR ANY JURISDICTION IN WHICH SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL. Ultimovacs ASA (OSE: ULTI) ("Ultimovacs" or the "Company") and Zelluna Immunotherapy AS ("Zelluna"), a privately held company pioneering the development of “off the shelf” T- Cell Receptor Natural Killer (TCR-NK) cell therapies for the treatment of solid cancers, today announces tha

GlobeNewswire last month

ULTI.OL

ULTIO.OL
Ultimovacs ASA (FRA:7UM) Q3 2024 Earnings Call Highlights: Strategic Advances Amidst Financial ...

Ultimovacs ASA (FRA:7UM) extends its cash runway and progresses in clinical trials, despite facing setbacks in cancer research and financial hurdles.

GuruFocus.com 2 months ago

7UM.F
-2.02%
Ultimovacs ASA Reports Third Quarter 2024 Financial Results and Provides General Business Update

Oslo, November 6, 2024: Ultimovacs ASA ("Ultimovacs") (OSE ULTI), a clinical-stage biotechnology company developing novel immunotherapies against cancer, announces its third quarter 2024 results today. Conference call and webcast scheduled for November 6, 2024, at 14:00 (CET). Link to webcast here. Third Quarter 2024 Business Update Highlights Ultimovacs implemented cash preservation initiatives during the second quarter of 2024. During the third quarter of 2024, additional cash preservation opp

GlobeNewswire 2 months ago

ULTI.OL

ULTIO.OL
Ultimovacs ASA: Invitation to third quarter 2024 results webcast presentation

Oslo, October 31, 2024: Ultimovacs ASA (“Ultimovacs”) (OSE ULTI), a clinical-stage biotechnology company developing immunotherapeutic cancer vaccines, invites to a webcast presentation of its third quarter 2024 results, on Wednesday, November 6, 2024. The presentation can be followed as a live webcast accessed through a link on www.ultimovacs.com at 14:00 CET on Wednesday, November 6, 2024. The webcast presentation will be available on the Ultimovacs website, and it will be possible to post ques

GlobeNewswire 3 months ago

ULTI.OL
Ultimovacs Announces Publication of Phase II FOCUS Trial Results on medRxiv

Oslo, October 25, 2024: Ultimovacs ASA (“Ultimovacs”) (OSE ULTI), a clinical-stage biotechnology company developing immunotherapeutic cancer vaccines, today announced that the results from Phase II FOCUS trial (NCT05075122) have been published online on the preprint platform medRxiv. As previously reported, topline data readout demonstrated that adding UV1 to the standard of care pembrolizumab did not lead to clinical benefits in progression free survival or overall survival in the late-stage he

GlobeNewswire 3 months ago

ULTI.OL

ULTIO.OL
Ultimovacs Announces Patient Recruitment Discontinuation in LUNGVAC Trial Investigating UV1 Combined with Checkpoint Inhibitor Therapy in Non-Small Cell Lung Cancer

Oslo, September 11, 2024: Ultimovacs ASA (“Ultimovacs”) (OSE ULTI), a clinical-stage biotechnology company developing immunotherapeutic cancer vaccines, today announced that the company has agreed with the investigators conducting the LUNGVAC trial (NCT05344209) to discontinue patient recruitment. LUNGVAC is an investigator-initiated, randomized Phase II trial designed to assess the impact of UV1 in combination with the checkpoint inhibitor cemiplimab or pembrolizumab as first-line treatment in

GlobeNewswire 4 months ago

ULTI.OL

ULTIO.OL
Ultimovacs Announces Updated Data Analysis on UV1 Phase II NIPU Trial in Mesothelioma at ESMO 2024

Oslo, September 9, 2024: Ultimovacs ASA (“Ultimovacs”) (OSE ULTI), a clinical-stage biotechnology company developing novel immunotherapies against cancer, announces the presentation of updated data analysis from the UV1 Phase II NIPU trial (NCT04300244), at the 2024 ESMO Congress. The NIPU trial evaluated the addition of UV1 telomerase vaccine to immunotherapy with ipilimumab and nivolumab compared with ipilimumab and nivolumab alone, as a second-line treatment for patients with inoperable malig

GlobeNewswire 4 months ago

ULTI.OL

ULTIO.OL
Ultimovacs ASA Reports Second Quarter 2024 Financial Results and Provides General Business Update

Oslo, August 21, 2024: Ultimovacs ASA ("Ultimovacs") (OSE ULTI), a clinical-stage biotechnology company developing novel immunotherapies against cancer, announces its second quarter 2024 results today. Conference call and webcast scheduled for August 21, 2024, at 14:00 (CET). Link to webcast here. Second Quarter 2024 Business Update Following the negative INITIUM result in March 2024, Ultimovacs implemented cash preservation initiatives during the second quarter of 2024 extending the anticipated

GlobeNewswire 5 months ago

ULTI.OL

ULTIO.OL
Ultimovacs ASA: Invitation to second quarter 2024 results webcast presentation

Oslo, August 15, 2024: Ultimovacs ASA (“Ultimovacs”) (OSE ULTI), a clinical-stage biotechnology company developing immunotherapeutic cancer vaccines, invites to a webcast presentation of its second quarter 2024 results on Wednesday, August 21, 2024. The presentation can be followed as a live webcast accessed through a link on www.ultimovacs.com at 14:00 CET on Wednesday, August 21, 2024, and is scheduled to conclude at 14:55 CET. The webcast presentation will be available on the Ultimovacs websi

GlobeNewswire 5 months ago

ULTI.OL

ULTIO.OL
Ultimovacs Announces Topline Data from FOCUS Phase II Trial of UV1 Combined with Pembrolizumab in Patients with Metastatic or Recurrent Head and Neck Cancer

Adding Ultimovacs’ cancer vaccine UV1 to checkpoint inhibitor pembrolizumab did not meet primary or secondary endpoints in patients with metastatic or recurrent head and neck squamous cell carcinomaUV1 continues to show a positive safety profile in line with other UV1 studies with similar events observed in the control arm and good tolerabilityAs previously communicated, financial runway secured until Q4 2025 beyond expected topline results from DOVACC Phase II study in 1H2025Within the availabl

GlobeNewswire 5 months ago

ULTI.OL
Ultimovacs Announces Poster Presentation of NIPU Phase II Trial Update at Upcoming ESMO Congress 2024

Oslo, August 1, 2024: Ultimovacs ASA (“Ultimovacs”) (OSE ULTI), a clinical-stage biotechnology company developing immunotherapeutic cancer vaccines, today announced that an update from the Phase II NIPU trial (NCT04300244) in patients with malignant mesothelioma will be presented in a poster presentation at the 2024 ESMO Congress. The conference will be held in Barcelona, Spain from September 13-17, 2024. Poster Presentation Details: Title: Updated survival and vaccine response from the NIPU tri

GlobeNewswire 5 months ago

ULTI.OL

ULTIO.OL
Ultimovacs ASA announces revised terms of the employee share option program

Oslo, June 24, 2024: Ultimovacs ASA (“Ultimovacs”) (OSE ULTI), a clinical-stage biotechnology company developing immunotherapeutic cancer vaccines, announces revised terms of the employee share option program. Ultimovacs has during the second quarter of this year implemented a cash preservation program that includes downsizing of the organization. As a measure to stimulate retention of non-redundant team members, the board of directors of Ultimovacs ASA has decided to revise the terms of parts o

GlobeNewswire 7 months ago

ULTI.OL

ULTIO.OL

Performance Overview

Return	7UM.F	OBX Total Return Index
YTD	-8.03%	+7.37%
1-Year	-98.59%	+22.27%
3-Year	-98.10%	+35.92%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Ultimovacs ASA (7UM.F)

Ultimovacs ASA (FRA:7UM) Q4 2024 Earnings Call Highlights: Strategic Merger and Financial Challenges

Ultimovacs ASA Reports Fourth Quarter 2024 Financial Results and Provides General Business Update

Ultimovacs ASA: Invitation to fourth quarter 2024 results webcast presentation

Ultimovacs ASA: Notification of major holdings

Ultimovacs ASA: Notice of extraordinary general meeting on 9 January 2024 - CORRECTION

Ultimovacs ASA: Notice of extraordinary general meeting on 9 January 2024

Key information relating to the potential subsequent repair offering to be carried out by Ultimovacs ASA

Ultimovacs ASA – Mandatory notification of trade

ULTIMOVACS ANNOUNCES AGREEMENT TO COMBINE ITS BUSINESS WITH ZELLUNA IMMUNOTHERAPY AND INTENTION TO LAUNCH FULLY COMMITTED PRIVATE PLACEMENT

Ultimovacs ASA (FRA:7UM) Q3 2024 Earnings Call Highlights: Strategic Advances Amidst Financial ...

Ultimovacs ASA Reports Third Quarter 2024 Financial Results and Provides General Business Update

Ultimovacs ASA: Invitation to third quarter 2024 results webcast presentation

Ultimovacs Announces Publication of Phase II FOCUS Trial Results on medRxiv

Ultimovacs Announces Patient Recruitment Discontinuation in LUNGVAC Trial Investigating UV1 Combined with Checkpoint Inhibitor Therapy in Non-Small Cell Lung Cancer

Ultimovacs Announces Updated Data Analysis on UV1 Phase II NIPU Trial in Mesothelioma at ESMO 2024

Ultimovacs ASA Reports Second Quarter 2024 Financial Results and Provides General Business Update

Ultimovacs ASA: Invitation to second quarter 2024 results webcast presentation

Ultimovacs Announces Topline Data from FOCUS Phase II Trial of UV1 Combined with Pembrolizumab in Patients with Metastatic or Recurrent Head and Neck Cancer

Ultimovacs Announces Poster Presentation of NIPU Phase II Trial Update at Upcoming ESMO Congress 2024

Ultimovacs ASA announces revised terms of the employee share option program

Performance Overview